Does the media prefer CNMD or OBIO?

In the previous week, Orchestra BioMed had 4 more articles in the media than CONMED. MarketBeat recorded 8 mentions for Orchestra BioMed and 4 mentions for CONMED. CONMED's average media sentiment score of 0.51 beat Orchestra BioMed's score of 0.44 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DRTS or OBIO?

In the previous week, Orchestra BioMed had 5 more articles in the media than Alpha Tau Medical. MarketBeat recorded 8 mentions for Orchestra BioMed and 3 mentions for Alpha Tau Medical. Orchestra BioMed's average media sentiment score of 0.44 beat Alpha Tau Medical's score of 0.05 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Tau Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Orchestra BioMed 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OBIO or STAA?

In the previous week, Orchestra BioMed had 2 more articles in the media than STAAR Surgical. MarketBeat recorded 8 mentions for Orchestra BioMed and 6 mentions for STAAR Surgical. Orchestra BioMed's average media sentiment score of 0.44 beat STAAR Surgical's score of 0.29 indicating that Orchestra BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral STAAR Surgical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor TNDM or OBIO?

In the previous week, Orchestra BioMed had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Orchestra BioMed and 6 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.24 beat Orchestra BioMed's score of 0.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BVS or OBIO?

In the previous week, Orchestra BioMed had 6 more articles in the media than Bioventus. MarketBeat recorded 8 mentions for Orchestra BioMed and 2 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 0.44 beat Bioventus' score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Orchestra BioMed 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Orchestra BioMed (OBIO) Competitors

$5.95 +0.22 (+3.84%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.75 -0.20 (-3.34%)

As of 10/9/2026 07:30 PM Eastern

Compare

OBIO vs. CNMD, DRTS, STAA, TNDM, and BVS

Should you buy Orchestra BioMed stock or one of its competitors? Orchestra BioMed's main competitors and comparable companies include CONMED (CNMD), Alpha Tau Medical (DRTS), STAAR Surgical (STAA), Tandem Diabetes Care (TNDM), and Bioventus (BVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Orchestra BioMed compare to CONMED?

CONMED (NYSE:CNMD) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

CONMED presently has a consensus target price of $41.40, suggesting a potential downside of 6.82%. Orchestra BioMed has a consensus target price of $13.17, suggesting a potential upside of 121.29%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than CONMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CONMED	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

53.2% of Orchestra BioMed shares are owned by institutional investors. 0.3% of CONMED shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Orchestra BioMed had 4 more articles in the media than CONMED. MarketBeat recorded 8 mentions for Orchestra BioMed and 4 mentions for CONMED. CONMED's average media sentiment score of 0.51 beat Orchestra BioMed's score of 0.44 indicating that CONMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CONMED	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CONMED has a net margin of 4.12% compared to Orchestra BioMed's net margin of -184.60%. CONMED's return on equity of 14.31% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CONMED	4.12%	14.31%	6.33%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

CONMED has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CONMED	$1.37B	0.97	$47.06M	$1.85	24.02
Orchestra BioMed	$33.48M	10.68	-$52.70M	-$0.85	N/A

CONMED has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

Summary

CONMED beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Alpha Tau Medical has higher earnings, but lower revenue than Orchestra BioMed. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$1.04	N/A
Orchestra BioMed	$33.48M	10.68	-$52.70M	-$0.85	N/A

Alpha Tau Medical has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

In the previous week, Orchestra BioMed had 5 more articles in the media than Alpha Tau Medical. MarketBeat recorded 8 mentions for Orchestra BioMed and 3 mentions for Alpha Tau Medical. Orchestra BioMed's average media sentiment score of 0.44 beat Alpha Tau Medical's score of 0.05 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alpha Tau Medical currently has a consensus price target of $15.40, suggesting a potential upside of 6.87%. Orchestra BioMed has a consensus price target of $13.17, suggesting a potential upside of 121.29%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Alpha Tau Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -184.60%. Alpha Tau Medical's return on equity of -138.12% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-138.12%	-81.68%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Summary

Orchestra BioMed beats Alpha Tau Medical on 10 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to STAAR Surgical?

Orchestra BioMed (NASDAQ:OBIO) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Orchestra BioMed had 2 more articles in the media than STAAR Surgical. MarketBeat recorded 8 mentions for Orchestra BioMed and 6 mentions for STAAR Surgical. Orchestra BioMed's average media sentiment score of 0.44 beat STAAR Surgical's score of 0.29 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
STAAR Surgical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 39.9% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Orchestra BioMed presently has a consensus target price of $13.17, indicating a potential upside of 121.29%. STAAR Surgical has a consensus target price of $28.45, indicating a potential upside of 31.31%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Orchestra BioMed is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
STAAR Surgical	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

Orchestra BioMed has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Orchestra BioMed has higher earnings, but lower revenue than STAAR Surgical. Orchestra BioMed is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	10.68	-$52.70M	-$0.85	N/A
STAAR Surgical	$239.44M	4.54	-$80.45M	$0.07	309.57

STAAR Surgical has a net margin of 1.13% compared to Orchestra BioMed's net margin of -184.60%. STAAR Surgical's return on equity of 9.05% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-184.60%	-149.61%	-54.15%
STAAR Surgical	1.13%	9.05%	6.99%

Summary

STAAR Surgical beats Orchestra BioMed on 9 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

In the previous week, Orchestra BioMed had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 8 mentions for Orchestra BioMed and 6 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.24 beat Orchestra BioMed's score of 0.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tandem Diabetes Care has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Tandem Diabetes Care currently has a consensus price target of $27.18, indicating a potential upside of 68.74%. Orchestra BioMed has a consensus price target of $13.17, indicating a potential upside of 121.29%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Tandem Diabetes Care.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.43
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Tandem Diabetes Care has a net margin of -6.08% compared to Orchestra BioMed's net margin of -184.60%. Tandem Diabetes Care's return on equity of -45.97% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Orchestra BioMed has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.10	-$204.71M	-$0.93	N/A
Orchestra BioMed	$33.48M	10.68	-$52.70M	-$0.85	N/A

53.2% of Orchestra BioMed shares are held by institutional investors. 2.1% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Orchestra BioMed beats Tandem Diabetes Care on 9 of the 17 factors compared between the two stocks.

How does Orchestra BioMed compare to Bioventus?

Bioventus (NASDAQ:BVS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Orchestra BioMed had 6 more articles in the media than Bioventus. MarketBeat recorded 8 mentions for Orchestra BioMed and 2 mentions for Bioventus. Orchestra BioMed's average media sentiment score of 0.44 beat Bioventus' score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bioventus has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 33.5% of Bioventus shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bioventus currently has a consensus price target of $16.80, indicating a potential upside of 28.64%. Orchestra BioMed has a consensus price target of $13.17, indicating a potential upside of 121.29%. Given Orchestra BioMed's higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Orchestra BioMed	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Bioventus has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.93	$22.73M	$0.77	16.96
Orchestra BioMed	$33.48M	10.68	-$52.70M	-$0.85	N/A

Bioventus has a net margin of 9.36% compared to Orchestra BioMed's net margin of -184.60%. Bioventus' return on equity of 28.08% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	9.36%	28.08%	9.82%
Orchestra BioMed	-184.60%	-149.61%	-54.15%

Summary

Bioventus beats Orchestra BioMed on 11 of the 15 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$344.40M	$5.44B	$7.16B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.36%
P/E Ratio	-7.00	25.57	274.15	26.16
Price / Sales	10.68	83.46	590.34	94.78
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	6.26	5.93	11.21	6.34
Net Income	-$52.70M	$146.18M	$3.50B	$381.90M
7 Day Performance	N/A	-0.38%	-0.90%	-1.41%
1 Month Performance	2.41%	-2.03%	-4.44%	-3.48%
1 Year Performance	88.89%	5.08%	6.96%	1.16%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	3.6036 of 5 stars	$5.95 +3.8%	$13.17 +121.3%	+107.3%	$344.40M	$33.48M	N/A	86
CNMD CONMED	2.052 of 5 stars	$44.18 -0.7%	$41.40 -6.3%	-2.2%	$1.32B	$1.37B	23.88	3,900	News Coverage Analyst Downgrade Gap Up
DRTS Alpha Tau Medical	1.7786 of 5 stars	$14.21 -1.9%	$15.40 +8.4%	+272.4%	$1.29B	N/A	N/A	121
STAA STAAR Surgical	4.0424 of 5 stars	$22.56 +1.9%	$28.45 +26.1%	-17.2%	$1.13B	$239.44M	320.63	957	Analyst Upgrade
TNDM Tandem Diabetes Care	2.8419 of 5 stars	$16.11 -0.3%	$27.18 +68.8%	+8.7%	$1.12B	$1.01B	N/A	2,500	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. CNMD, DRTS, STAA, TNDM, and BVS

How does Orchestra BioMed compare to CONMED?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Summary

How does Orchestra BioMed compare to STAAR Surgical?

Summary

How does Orchestra BioMed compare to Tandem Diabetes Care?

Summary

How does Orchestra BioMed compare to Bioventus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. CNMD, DRTS, STAA, TNDM, and BVS

How does Orchestra BioMed compare to CONMED?

Do analysts prefer CNMD or OBIO?

Do insiders & institutionals hold more shares of CNMD or OBIO?

Does the media prefer CNMD or OBIO?

Is CNMD or OBIO more profitable?

Which has stronger valuation and earnings, CNMD or OBIO?

Which has more volatility and risk, CNMD or OBIO?

Summary

How does Orchestra BioMed compare to Alpha Tau Medical?

Which has higher valuation and earnings, DRTS or OBIO?

Which has more volatility and risk, DRTS or OBIO?

Does the media refer more to DRTS or OBIO?

Do insiders & institutionals hold more shares of DRTS or OBIO?

Do analysts rate DRTS or OBIO?

Is DRTS or OBIO more profitable?

Summary

How does Orchestra BioMed compare to STAAR Surgical?

Does the media prefer OBIO or STAA?

Do institutionals and insiders believe in OBIO or STAA?

Do analysts prefer OBIO or STAA?

Which has more volatility and risk, OBIO or STAA?

Which has better earnings and valuation, OBIO or STAA?

Is OBIO or STAA more profitable?

Summary

How does Orchestra BioMed compare to Tandem Diabetes Care?

Does the media favor TNDM or OBIO?

Which has more risk & volatility, TNDM or OBIO?

Do analysts prefer TNDM or OBIO?

Is TNDM or OBIO more profitable?

Which has better valuation and earnings, TNDM or OBIO?

Do institutionals & insiders have more ownership in TNDM or OBIO?

Summary

How does Orchestra BioMed compare to Bioventus?

Does the media refer more to BVS or OBIO?

Which has more risk & volatility, BVS or OBIO?

Do institutionals & insiders have more ownership in BVS or OBIO?

Do analysts recommend BVS or OBIO?

Which has better earnings and valuation, BVS or OBIO?

Is BVS or OBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools